Trial Profile
Swiss Restless Legs Syndrome Trial (SRLS) A Double-blind, Randomised, Crossover Trial Investigating the Efficacy and Safety of the Dopamine Agonist Pramipexole (Sifrol®, 0.25-0.75 mg Per Day) Versus Levodopa / Benserazide (Madopar® DR, 125-375 mg Per Day) in Patients With Restless Legs Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2013
Price :
$35
*
At a glance
- Drugs Pramipexole (Primary) ; Levodopa/benserazide
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Acronyms SRLS
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 01 Nov 2011 Results published in the Swiss Medical Weekly.
- 04 Sep 2006 Status change
- 18 Nov 2005 New trial record.